{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Quinidine+placebo", "query": { "intervention": "Quinidine placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 25, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Quinidine+placebo&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-19T05:10:34.326Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02446132", "title": "Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Agitation in Patients With Dementia of the Alzheimer's Type" ], "interventions": [ { "name": "AVP-786", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 1197, "start_date": "2015-11-13", "completion_date": "2024-09-06", "has_results": true, "last_update_posted_date": "2025-10-15", "last_synced_at": "2026-09-19T05:10:34.326Z", "location_count": 171, "location_summary": "Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 103 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02446132" }, { "nct_id": "NCT00573443", "title": "Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pseudobulbar Affect (PBA)" ], "interventions": [ { "name": "dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg", "type": "DRUG" }, { "name": "dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avanir Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 326, "start_date": "2007-12", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2017-04-12", "last_synced_at": "2026-09-19T05:10:34.326Z", "location_count": 45, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 39 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00573443" }, { "nct_id": "NCT01806857", "title": "Clinical Trial Nuedexta in Subjects With ALS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Amyotrophic Lateral Sclerosis (ALS)" ], "interventions": [ { "name": "Nuedexta", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Center for Neurologic Study, La Jolla, California,", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2013-04", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2017-03-24", "last_synced_at": "2026-09-19T05:10:34.326Z", "location_count": 7, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Grand Rapids, Michigan + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01806857" }, { "nct_id": "NCT03420222", "title": "Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intermittent Explosive Disorder" ], "interventions": [ { "name": "AVP-786", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 10, "start_date": "2018-01-18", "completion_date": "2018-12-28", "has_results": true, "last_update_posted_date": "2022-05-24", "last_synced_at": "2026-09-19T05:10:34.326Z", "location_count": 9, "location_summary": "Gainesville, Florida • Atlanta, Georgia • Chicago, Illinois + 6 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New Bedford", "state": "Massachusetts" }, { "city": "O'Fallon", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03420222" }, { "nct_id": "NCT01584440", "title": "Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Agitation", "Alzheimer's Disease" ], "interventions": [ { "name": "AVP-923-20", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "AVP-923-30", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avanir Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 220, "start_date": "2012-08-13", "completion_date": "2014-07-30", "has_results": true, "last_update_posted_date": "2021-11-26", "last_synced_at": "2026-09-19T05:10:34.326Z", "location_count": 44, "location_summary": "Phoenix, Arizona • Sun City, Arizona • Fresno, California + 36 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01584440" }, { "nct_id": "NCT03393520", "title": "Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Agitation in Patients With Dementia of the Alzheimer's Type" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "AVP-786", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 601, "start_date": "2017-10-13", "completion_date": "2023-12-14", "has_results": false, "last_update_posted_date": "2024-11-20", "last_synced_at": "2026-09-19T05:10:34.326Z", "location_count": 93, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 68 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03393520" }, { "nct_id": "NCT06717269", "title": "A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "NX-5948", "type": "DRUG" }, { "name": "Esomeprazole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Famotidine", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Quinidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nurix Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "19 Years to 55 Years" }, "enrollment_count": 223, "start_date": "2024-11-30", "completion_date": "2026-05-01", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-09-19T05:10:34.326Z", "location_count": 2, "location_summary": "Phoenix, Arizona • Lincoln, Nebraska", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06717269" }, { "nct_id": "NCT02402595", "title": "Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "AVP-923", "type": "DRUG" }, { "name": "AVP-786", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 24, "start_date": "2015-03-01", "completion_date": "2015-07-01", "has_results": false, "last_update_posted_date": "2026-04-28", "last_synced_at": "2026-09-19T05:10:34.326Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02402595" }, { "nct_id": "NCT01767129", "title": "Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dyskinesia", "Parkinson's Disease" ], "interventions": [ { "name": "AVP-923-45", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avanir Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "30 Years to 80 Years" }, "enrollment_count": 14, "start_date": "2013-10-16", "completion_date": "2015-02-05", "has_results": true, "last_update_posted_date": "2022-04-29", "last_synced_at": "2026-09-19T05:10:34.326Z", "location_count": 2, "location_summary": "Chicago, Illinois • Portland, Oregon", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01767129" }, { "nct_id": "NCT02534038", "title": "Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Disinhibition Syndrome" ], "interventions": [ { "name": "AVP-786", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 1, "start_date": "2015-12-01", "completion_date": "2017-10-03", "has_results": true, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-09-19T05:10:34.326Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT02534038" } ] }